Abstract
The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress made in the development of inhibitors of sulfur metabolism enzymes.
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design and inhibitors.
Infectious Disorders - Drug Targets
Title:New Targets and Inhibitors of Mycobacterial Sulfur Metabolism
Volume: 13 Issue: 2
Author(s): Hanumantharao Paritala and Kate S. Carroll
Affiliation:
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design and inhibitors.
Abstract: The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress made in the development of inhibitors of sulfur metabolism enzymes.
Export Options
About this article
Cite this article as:
Paritala Hanumantharao and Carroll S. Kate, New Targets and Inhibitors of Mycobacterial Sulfur Metabolism, Infectious Disorders - Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/18715265113139990022
DOI https://dx.doi.org/10.2174/18715265113139990022 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bedside Balance Testing in Elderly People
Current Aging Science Editorial [Hot Topic: Carbonic Anhydrase Inhibitors (Guest Editor: Claudiu T. Supuran)]
Current Topics in Medicinal Chemistry “Big Three” Infectious Diseases: Tuberculosis, Malaria and HIV/AIDS
Current Topics in Medicinal Chemistry Gammadelta T Lymphocytes Producing IFNγ and IL-17 in Response to Candida Albicans or Mycobacterial Antigens: Possible Implications for Acute and Chronic Inflammation
Current Medicinal Chemistry Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Clinical Application of Percutaneous Puncture Biopsy Guided by Fused and 3D-reconstructed PET/CT Images
Current Medical Imaging Synthesis, Biological Evaluation and Computational Study of New Quinoline Hybrids as Antitubercular Agent
Letters in Drug Design & Discovery High Throughput Mutation Screening by Automated Capillary Electrophoresis
Combinatorial Chemistry & High Throughput Screening Macrolide Resistance Based on the Erm-mediated rRNA Methylation
Current Drug Targets - Infectious Disorders Editorial: An Emerging Immunogenomics and Computational Approach for Peptide Vaccinology: Rational Design of Peptide Vaccines
Current Computer-Aided Drug Design Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Targeting Toll-Like Receptor Signaling Pathways for Design of Novel Immune Therapeutics
Current Drug Discovery Technologies Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Combating Diseases with Computational Strategies Used for Drug Design and Discovery
Current Topics in Medicinal Chemistry Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design